Regulatory Affairs & Market Entry

Regulatory intelligence & market entry

Before we build your value story, we map the landscape and the partners

Regulatory intelligence and market entry is the first of Veridian’s three services, the entry point that sets up the value and medical work that follow. A distributor gets you in-country, not HTA-ready; this practice closes that gap.

Who It's for

Market Entrants

Regional Affiliates

Global Launch Teams

Policy & Regulatory Bodies

Regulatory Intelligence

Continuous Monitoring, Expert-Interpreted

  • Six-market monitoring Saudi Arabia, UAE, Qatar, Kuwait, Bahrain and Oman
  • Registration, pricing, HTA & formulary tracking
  • Policy & guidance document classification

Outcome: Current landscape not last year’s desk research.

Distributor & Partner Matching

Distributor network & Selection support

  • Distributor Network: capabilities, TA coverage, track record
  • Distributor Selection support
  • Conflict-of-interest screening & disclosure

Outcome: Evidence-based partner selection not just who we know

Market Entry Diagnostic

The expanded front door

  • What is the regulatory landscape for your asset right now?
  • Who are the viable local partners, and what are the conflicts?
  • Where does your global evidence need local translation?
  • Recommended entry path: market sequence, partners, workstreams

Outcome: Four questions answered in one diagnostic

Regulatory & Policy Monitoring

Regional intelligence

  • Regular updates per market & TA
  • Serves manufacturers and policy/regulatory clients alike

Outcome: Recurring intelligence Veridian stays in your decision cycle

Take the next step towards GCC market entry

Bring us your regulatory or market entry challenge. From understanding local requirements to managing submissions and lifecycle operations, Veridian brings senior-led support to your regulatory strategy across the six GCC markets.
Book Your Diagnostic

Get GCC Access Insights

Practical thinking on registration, HTA, pricing and clinical adoption across the GCC, plus details of upcoming Veridian events.

Ajaz Rashid

Medical affairs & scientific communications

Over 30 years in medical affairs, scientific communications and clinical research in global, regional and local roles. Successful track record in leading people and teams to develop and deliver scientific narratives, programmes and content with demonstrable HCP impact across multiple therapeutic areas including respiratory, immunology, oncology, CV, metabolic, neurology and hepatology.

Dr. Rashmi Hegde

Medical affairs

30 years delivering 80+ Life Sciences product & vaccine regulatory approvals for launches across therapies and geographies. Expertise in Pharmacovigilance, Medical, Clinical, patient affairs, and medical governance. Optimized MA & MSL capabilities, focusing on executional excellence. Achieved 100% PV compliance across 33 global affiliates

Dr. Laura Jotimliansky

Medical affairs & clinical research

30+ years in pharma across multiple TAs and geographies. Internal Medicine and Clinical Pharmacology training with deep LATAM and Middle East focus. At GSK, led regional teams and built Oncology structure across Emerging Markets. Previously at BMS and Roche.

Dr. Elif Coskuncay

Medical affairs

25+ years spanning pharma, clinical practice, and strategic medical affairs at global, regional, and local levels. Therapeutic expertise in oncology, cardiovascular, metabolic, respiratory, rare diseases, and vaccines. Successfully launched life-saving therapies including immuno-oncology in emerging and developed markets.

Rafa Al Khalifa

Market access & stakeholder engagement

Healthcare strategy consultant specializing in specialty pharmacy, market access, patient support programs, health economics, quality, and compliance. UAE MOHAP-registered pharmacist. Led the first ACHC-accredited specialty pharmacy outside the US. FIP SAPS Executive Committee member; represented FIP at the World Health Assembly and COP29. Co-Founder of EcoRx UAE.

Dr. Claudia Soares

Rwe, heor & business intelligence

Physician with MSc/PhD in Epidemiology & Biostatistics and a Master’s in Business Intelligence (focused on AI in healthcare). Over 18 years of experience across academia, government, and the pharmaceutical industry in R&D, Health Outcomes, and Medical Affairs. Led global, regional, and local projects in clinical development, launch planning, epidemiology, health outcomes, real-world data (RWD), and evidence generation, with a strong track record of impact in emerging markets.

Dr. Ali AlHammad

Heor & market access

HEOR expert with strong background in market access, patient-reported outcomes, and medical research. Proven track record developing strategic brand plans for successful launches in Saudi Arabia. Deep understanding of the Saudi healthcare system, translating complex economic data into actionable insights for payers.

Safinaz Issa

Regulatory affairs & market access

Senior Regulatory, Government Affairs & Market Access Executive with 25+ years of leadership across Pfizer, GSK, Sanofi Genzyme, Novartis, Eisai, and Eli Lilly. Led 1,000+ filings and market access strategies across 40+ markets in MEA, Europe, and North America. Expertise spans regulatory strategy and intelligence, health authority engagement, compliance, lifecycle management, and complex product launches across rare diseases, neuroscience, oncology, and medical devices.

Dr. Razia Hussain

Director, Medical Affairs

Senior Medical Affairs and Clinical Research leader with 25+ years of international pharmaceutical experience across Oncology, Immunology, Cardiovascular, Respiratory, HIV, Hepatology, and Specialty Medicine. Led Medical Affairs teams in China and clinical research operations globally, delivering registration studies, evidence generation, pre-launch readiness, and RWE programmes. Developed medical excellence capabilities adopted as global best practices, led a major cardiovascular RWE study in the Middle East, and established a regional pharmacovigilance hub for Africa. Strong track record in medical strategy, cross-functional leadership, stakeholder engagement, and building high-performing teams.

Fayaz Aziz

Managing Director, HTA/HEOR and Market Access

Senior health economics, market access, and medical affairs leader with 25+ years of international experience spanning industry, government, academia, and consultancy across R&D, EU, Emerging Markets, and the Middle East. Led HEOR strategy and medical excellence across 30+ markets at GSK, delivered HTA submissions to NICE and SMC at Pfizer UK, and founded a global HEOR Academy that trained 2,000+ professionals. 15+ years in the GCC, with early career foundations as a public health scientist at the England Department of Health, health policy training at LSE, and doctoral research at LSHTM on AI governance in HTA decision-making.